Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 38,347

Document Document Title
WO/2018/011164A1
The present invention relates to a compound of formula (I) wherein R1 is phenyl, lower alkyl, C3-6-cycloalkyl, -CH2-C3-6-cycloalkyl or bridged C4-6-cycloalkyl, substituted by one, two or three halogen atoms, or by lower alkyl or lower al...  
WO/2018/011017A1
The invention relates to novel 7 substituted l-pyridyl-naphthyridine-3-carboxylic acid amides, to methods for producing the same, to the use thereof either alone or in combination in the treatment and/or prevention of diseases and to the...  
WO/2018/013774A1
Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII); or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted...  
WO/2018/011160A1
The present invention relates to compounds of the formula (I) or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 are as described above. The compounds may be useful for the treatment or prophylaxis...  
WO/2018/011100A1
The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R5 are as described above. The compounds may be useful for the treatment or prophylaxi...  
WO/2018/011681A1
Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, a...  
WO/2018/013534A1
The present invention relates to methods for treating PTEN deficient epithelial cancers using a combination of anti-PI3Kbeta and anti-immune checkpoint agents.  
WO/2018/011138A1
Compound of formula (I´) or (I´´) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders a...  
WO/2018/013482A1
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N oxides, and salts thereof, wherein A, X1, X2, X3 and R2 are as defined in the disclosure. Also disclosed are compositions containing the compounds of Form...  
WO/2018/013772A1
Disclosed are compounds of Formulas (I), (II), (III), (IV), (V), (VI), (VII), or (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII) or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a...  
WO/2018/011227A1
The invention relates to a compound of Formula I : Formula I, or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of tryptophan 2...  
WO/2018/011090A1
The present invention relates to compounds acting both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists, to processes for their preparation, to compositions comprising them, to therapeutic uses and combinations w...  
WO/2018/011570A1
The present invention relates to compounds that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compound...  
WO/2018/009735A1
Solid state forms of Palbociclib dimesylate, processes for preparation thereof and use thereof for preparation of Palbociclib are disclosed.  
WO/2018/006680A1
Provided is a compound as represented by formula (I), wherein a 9,9'-spirobifluorene is linked to the 1-, 2-, 3-, or 4-position. Ar1 and Ar2 are respectively a C6-C25 aryl group, the C6-C25 aryl group is either unsubstituted or substitut...  
WO/2018/009417A1
Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to macrocyclic α-keto amide derivatives and their use as therapeutic agents.  
WO/2018/006756A1
A chiral heterocyclic compound with hedgehog pathway antagonist activity, method and use thereof are provided. The chiral heterocyclic compound with hedgehog pathway antagonist activity has the structure represented by formula I. A pharm...  
WO/2018/008718A1
[Problem] To provide an organic compound having excellent characteristics, which exhibits, as a material for organic electroluminescent elements having high efficiency and high durability, excellent electron injection/transport performan...  
WO/2018/007249A1
The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.  
WO/2018/008929A1
The present disclosure relates to novel imidazo[1,2-a]pyridine derivatives, and more particularly to imidazo[1,2-a]pyridine derivatives having an excellent activity of inhibiting gastric acid secretion, methods for preparing the same, an...  
WO/2018/009627A1
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inve...  
WO/2018/009625A1
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inve...  
WO/2018/007927A1
The present application relates to a process for the preparation of crystalline form A of palbociclib having specific surface area more than 2m2/g comprising one-pot process for the preparation of compound of formula (IV). The present ap...  
WO/2018/009007A1
The present application provides: a heterocyclic compound capable of greatly improving the lifespan, efficiency, electrochemical stability, and thermal stability of an organic light emitting device; and an organic light emitting device h...  
WO/2018/006679A1
An organic electron transport device with high glass transition temperature (Tg), comprising: an anode, a cathode, and an organic layer. The anode and cathode are constructed using a metal, an inorganic material, or an organic compound. ...  
WO/2018/009938A1
Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure [Formula should be inserted here] and pharmaceutically acceptable salts, prodrugs and...  
WO/2018/008442A1
The purpose of the present invention is to provide: a π-conjugated compound exhibiting excellent light emission characteristics; an organic electroluminescent element using same; a display device; and an illumination device. Accordingly...  
WO/2018/002760A1
The present invention provides, in part, compounds of Formula (I): or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N- oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the prep...  
WO/2018/000550A1
Disclosed is a pyrazolo [3,4-d] pyrimidine derivative represented by the formula (I), having a significant inhibitory effect on tumour cells, and being used for the prevention or treatment of tumour-related diseases, particularly lung ca...  
WO/2018/001952A1
The present invention provides novel compounds having general formula (I), wherein R1 to R4, A, W, Q and Y are as described herein, compositions including the compounds and methods of using the compounds.  
WO/2018/004319A2
The present specification relates to a heterocyclic compound of chemical formula 1 and an organic light emitting element comprising the same.  
WO/2018/003962A1
2- (Piperidin-1-yl) pyrimidin-4 (3H) -ones characterized by having a 1,8-diazaspiro [4.5] deca-3-ene, 1-oxa-8-azaspiro [4.5] deca-3-ene, 2,8-diazaspiro [4.5] deca-3-ene, 2-oxa-8-azaspiro [4.5] deca-3-ene, 2,9-diazaspiro [5.5] undeca-3-en...  
WO/2018/002437A1
Compounds of formula (I): wherein Ra and Rb are as defined in the claims, exhibit alpha2C antagonistic activity and are thus useful as alpha2C antagonists.  
WO/2018/005883A1
Provided herein are compounds of formula (I) and (V) useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the ...  
WO/2018/005881A1
Provided herein are compounds of formula (IA) and (III) useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in t...  
WO/2018/005586A1
Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9,...  
WO/2018/003531A1
The present invention provides a pyrroloquinone quinone monosodium having a structure represented by formula (1).  
WO/2018/001948A1
The present invention relates to compounds of formula (I): (I) or pharmaceutically acceptable salts thereof, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.  
WO/2018/001232A1
The present invention relates to an acrylic acid-based derivative as represented by a general formula (I), stereoisomers and tautomers thereof, or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutica...  
WO/2018/000549A1
A [1,2,4] triazolo [1,5-a] pyridine derivative as shown in formula (I) and a crystalline form thereof. The compound has a significant inhibitory effect against tumor cells, is applicable in preventing and/or treating tumor-related diseas...  
WO/2018/003701A1
The present invention addresses the problem of providing an organic thin-film transistor with which a high carrier mobility is maintained even in the atmosphere and a manufacturing method therefor. Solutions for solving the aforementione...  
WO/2018/002415A1
The present invention relates to novel processes for the manufacture of N-(3-(5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbony l)-2,4-difluorophenyl)propane-1-sulfonamide (I), wherein no protection-deprotection sequences or halogen...  
WO/2018/002848A1
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, azadecaline derivatives that possess unique antiviral activity are provided as HIV maturation inhibito...  
WO/2018/005591A1
The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of ...  
WO/2018/001918A1
The present invention relates to compounds of formula (I) HetAr is a five or six membered hetaryl group, containing one, two or three heteroatoms, selected from N, O or S; R1 is hydrogen, lower alkyl, lower alkyl substituted by halogen, ...  
WO/2018/004258A1
The present invention relates to a novel heterocyclic derivative compound and a use thereof and, more particularly, to a novel heterocyclic derivative compound having selective inhibitory activity against a fibroblast growth factor recep...  
WO/2018/003976A1
In agricultural and horticultural crop production, etc., damage by pests and the like remains devastating even today, and due to factors such as the occurrence of pests resistant to existing chemicals, there is a demand for the developme...  
WO/2018/002219A1
Fused aromatic bicyclic substituted 5-(2-amino-4-pyrimidinyl)- cyanoindoline derivatives (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-KB-inducing kinase (NIK - also known as MAP3K14) useful...  
WO/2018/005177A1
The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these co...  
WO/2018/001270A1
Disclosed herein are Palbociclib prodrugs, and pharmaceutical compositions comprising the Palbociclib prodrugs.  

Matches 1 - 50 out of 38,347